# Ki Values Solution Plan - Comprehensive Fix for Unreliable Ki Predictions

## ðŸ” Problem Analysis

### Root Cause Identified:
**The Gnosis I model was NEVER trained on real Ki data**, despite the infrastructure being designed for it.

### Evidence:
- **Training Data**: Only contains IC50 ('B') and functional ('F') assays - NO Ki values
- **Model Predictions**: Ki shows 750,000+ Î¼M (essentially "no binding") with 99% confidence
- **Infrastructure**: Code supports Ki but actual training data missing

## ðŸ› ï¸ Immediate Solution (Phase 1)

### 1. Honest Reporting in UI
```javascript
// Frontend: Clear indication of Ki limitations
if (assayType === 'Ki' && activityUM > 100000) {
  return {
    primaryText: "Not trained",
    secondaryText: "(Ki unavailable)", 
    isExtreme: true,
    isUnreliable: true
  };
}
```

### 2. Model Training Notice
```html
âš ï¸ Ki Predictions: This model was trained primarily on IC50 data. 
Ki predictions are extrapolations and should not be used for binding affinity analysis.
```

## ðŸš€ Comprehensive Solution (Phase 2)

### 1. Data Extraction Enhancement
- **ChEMBL API**: Extract Ki values using `standard_type__in: 'Ki,Kd'` 
- **BindingDB**: Include actual Ki measurements from binding assays
- **Target Coverage**: 14 key oncology targets with comprehensive assay data

### 2. Expected Data Distribution
Based on ChEMBL analysis:
- **IC50**: ~60-70% (primary binding data)
- **Ki**: ~20-25% (direct binding affinity)  
- **EC50**: ~10-15% (functional activity)
- **Kd**: ~5% (dissociation constant)

### 3. Training Data Requirements
- **Minimum Ki records**: 1,000+ for reliable training
- **Quality filters**: 
  - Activity range: 1 pM - 1 mM
  - Exact measurements only (`standard_relation = '='`)
  - Valid SMILES strings
- **Data balance**: Ensure each target has Ki representation

## ðŸ“Š Implementation Strategy

### Phase 1: Immediate (1-2 days)
1. âœ… Update UI to clearly indicate Ki limitations  
2. âœ… Add educational warnings about model training data
3. âœ… Implement quality flags for unreliable predictions
4. âœ… Create comprehensive tooltips explaining assay types

### Phase 2: Data Collection (1 week)
1. ðŸ”„ Extract comprehensive ChEMBL Ki data for 14 oncology targets
2. ðŸ”„ Include BindingDB Ki measurements 
3. ðŸ”„ Create balanced training dataset with IC50/Ki/EC50
4. ðŸ”„ Validate data quality and distribution

### Phase 3: Model Retraining (1-2 weeks)
1. â³ Retrain Gnosis I with multi-assay data
2. â³ Implement assay-specific loss functions
3. â³ Validate Ki predictions against held-out test set
4. â³ Deploy updated model with reliable Ki predictions

## ðŸŽ¯ Success Criteria

### Current State:
- âŒ Ki: 750,000 Î¼M (unreliable)
- âœ… IC50: 3-43 Î¼M (good)
- âœ… EC50: 3-297 Î¼M (good)

### Target State (Post-Retraining):
- âœ… Ki: 1-100 Î¼M range (reliable)
- âœ… IC50: Maintained quality
- âœ… EC50: Maintained quality
- âœ… RÂ² > 0.5 for all assay types

## ðŸ§ª Validation Plan

### 1. Literature Validation
- Compare predicted Ki vs published values for known drugs
- Examples: Imatinib (ABL1), Erlotinib (EGFR), Vemurafenib (BRAF)

### 2. Cross-Assay Consistency
- Ki should correlate with IC50 (Ki â‰ˆ IC50/2 typically)
- EC50 should be in similar range for competitive inhibitors

### 3. Chemical Series Analysis
- Similar molecules should have similar Ki values
- SAR (Structure-Activity Relationships) should be consistent

## ðŸ“ˆ Expected Impact

### Scientific Accuracy:
- **Before**: Ki predictions misleading (>99% confidence but wrong)
- **After**: Ki predictions reliable for drug discovery decisions

### User Trust:
- **Before**: Users may make wrong decisions based on false Ki data
- **After**: Users can confidently use Ki for binding affinity analysis

### Platform Credibility:
- **Before**: Major limitation undermines pharmaceutical applications
- **After**: Comprehensive binding data supports full drug discovery pipeline

## ðŸ”„ Rollback Plan

If Phase 2/3 fails:
1. Keep Phase 1 improvements (honest reporting)
2. Hide Ki predictions entirely until proper training
3. Focus on IC50/EC50 reliability as core value proposition

---

**Priority**: HIGH - Ki predictions currently misleading users
**Timeline**: Phase 1 (immediate), Phase 2-3 (2-3 weeks)
**Risk**: Medium - Requires significant data collection and retraining